Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)
Contineum Therapeutics (CTNM) recorded quarterly Long-Term Debt Repayments of $3.1 million in Q2 2023, up 400.0% quarter-over-quarter from $625000.0 in Q1 2023.
Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023) Analysis & Trends
Contineum Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $3.1 million for Q2 2023.
- In Q2 2023, Long-Term Debt Repayments changed N/A year-over-year to $3.1 million; the TTM figure through Mar 2024 stood at $3.1 million (changed N/A YoY), while the FY2023 annual figure was $3.8 million, changed N/A from the prior year.
- Long-Term Debt Repayments was $3.1 million for Q2 2023 at Contineum Therapeutics, up from $625000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $3.1 million in Q2 2023 to a low of $625000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Contineum Therapeutics | 430.52 Mn | 430.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 625,000.00 |
| Mar 31, 2023 | 625,000.00 |